# LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

> **NCT01466660** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 319 (actual)

## Conditions studied

- Lung Neoplasms

## Interventions

- **DRUG:** Afatinib
- **DRUG:** gefitinib

## Key facts

- **NCT ID:** NCT01466660
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-13
- **Primary completion:** 2016-04-08
- **Final completion:** 2019-04-12
- **Target enrollment:** 319 (ACTUAL)
- **Last updated:** 2020-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01466660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01466660, "LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01466660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*